 | Up a level |
Follows, G., Fischer, K., Bosch, F., Frederiksen, H., Cuneo, A., Ludwig, H., Crompton, N., Maurer, J., Uguen, M., Fingerle-Rowson, G., Hallek, M. and Goede, V. (2016). An updated survival analysis from the CLL11 study in patients with chronic lymphocytic leukaemia treated with obinutuzumab or rituximab in combination with chlorambucil versus chlorambucil alone. Br. J. Haematol., 173. S. 95 - 96. HOBOKEN: WILEY-BLACKWELL. ISSN 1365-2141
Freeman, C., Dixon, M., Houghton, R., Humphrey, K., Fingerle-Rowson, G., Kreuzer, K. A., Engelke, A., Hallek, M. and Goede, V. (2015). Risk factors associated with the development of infusion-related reactions (IRRs) in patients with chronic lymphocytic leukaemia (CLL) treated with anti-CD20 monoclonal antibodies (mAbs) in combination with chlorambucil: analysis of the prospective, randomised phase III CLL11 study dataset. Br. J. Haematol., 169. S. 63 - 64. HOBOKEN: WILEY-BLACKWELL. ISSN 1365-2141
Freeman, C., Dixon, M., Houghton, R., Humphrey, K., Fingerle-Rowson, G., Kreuzer, K. A., Engelke, A., Hallek, M. and Goede, V. (2015). Risk factors associated with the development of infusion-related reactions (IRRs) in patients with chronic lymphocytic leukaemia (CLL) treated with anti-CD20 monoclonal antibodies (mAbs) in combination with chlorambucil: analysis of the prospective, randomised phase III CLL11 study dataset. Br. J. Haematol., 169. S. 63 - 64. HOBOKEN: WILEY-BLACKWELL. ISSN 1365-2141
Freeman, C., Morschhauser, F., Sehn, L., Dixon, M., Houghton, R., Lamy, T., Fingerle-Rowson, G., Wassner-Fritsch, E., Hallek, M., Salles, G. and Cartron, G. (2015). Pattern of cytokine release in patients with chronic lymphocytic leukaemia treated with obinutuzumab and possible relationship with development of infusion related reactions (IRR). Br. J. Haematol., 169. S. 64 - 65. HOBOKEN: WILEY-BLACKWELL. ISSN 1365-2141
Freeman, C., Morschhauser, F., Sehn, L., Dixon, M., Houghton, R., Lamy, T., Fingerle-Rowson, G., Wassner-Fritsch, E., Hallek, M., Salles, G. and Cartron, G. (2015). Pattern of cytokine release in patients with chronic lymphocytic leukaemia treated with obinutuzumab and possible relationship with development of infusion related reactions (IRR). Br. J. Haematol., 169. S. 64 - 65. HOBOKEN: WILEY-BLACKWELL. ISSN 1365-2141
Freeman, C. L., Dixon, M., Houghton, R., Kreuzer, K-A, Fingerle-Rowson, G., Herling, M., Humphrey, K., Boettcher, S., de Costa, C. S., Iglesias, V., Stilgenbauer, S., Gribben, J., Hallek, M. and Goede, V. (2016). Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab. Leukemia, 30 (8). S. 1763 - 1768. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Goede, V., Fischer, K., Engelke, A., Schlag, R., Lepretre, S., Montero, L. F. C., Montillo, M., Fegan, C., Asikanius, E., Humphrey, K., Fingerle-Rowson, G. and Hallek, M. (2015). Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia, 29 (7). S. 1602 - 1606. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A. M., Busch, R., Mayer, J., Hensel, M., Hopfinger, G., Hess, G., von Gruenhagen, U., Bergmann, M., Catalano, J., Zinzani, P. L., Caligaris-Cappio, F., Seymour, J. F., Berrebi, A., Jaeger, U., Cazin, B., Trneny, M., Westermann, A., Wendtner, C. M., Eichhorst, B. F., Staib, P., Buehler, A., Winkler, D., Zenz, T., Boettcher, S., Ritgen, M., Mendila, M., Kneba, M., Doehner, H. and Stilgenbauer, S. (2010). Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet, 376 (9747). S. 1164 - 1175. NEW YORK: ELSEVIER SCIENCE INC. ISSN 0140-6736
Ritgen, M., Langerak, A., Goede, V., Bahlo, J., Kluth, S., Fischer, K., Steurer, M., Trneny, M., Mulligan, S., Mey, U., Trunzer, K., Humphrey, K., Fingerle-Rowson, G., Stilgenbauer, S., Boettcher, S., Bruggemann, M., Hallek, M., Kneba, M. and van Dongen, J. (2016). QUANTITATIVE MRD IS PROGNOSTIC FOR PROGRESSION-FREE & OVERALL SURVIVAL IN ELDERLY PATIENTS RECEIVING CHLORAMBUCIL ALONE OR WITH OBINUTUZUMAB/RITUXIMAB: A PROSPECTIVE ANALYSIS OF THE GCLLSG CLL11 STUDY. Haematologica, 101. S. 149 - 151. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Skazik, C., Heise, R., Czaja, K., Marquardt, Y., Dewor, M., Merk, H. F., Fingerle-Rowson, G., Bernhagen, J. and Baron, J. M. (2015). The chemokines MIF (macrophage migration inhibitory factor) and MIF-2/DDT (D-dopachrome tautomerase) as key mediators in the pathogenesis of cutaneous squamous cell carcinoma. Exp. Dermatol., 24 (3). S. E35 - 2. HOBOKEN: WILEY-BLACKWELL. ISSN 1600-0625
Skazik, C., Heise, R., Czaja, K., Marquardt, Y., Dewor, M., Merk, H. F., Fingerle-Rowson, G., Bernhagen, J. and Baron, J. M. (2015). The chemokines MIF (macrophage migration inhibitory factor) and MIF-2/DDT (D-dopachrome tautomerase) as key mediators in the pathogenesis of cutaneous squamous cell carcinoma. Exp. Dermatol., 24 (3). S. E35 - 2. HOBOKEN: WILEY-BLACKWELL. ISSN 1600-0625
Stark, K., Pekayvaz, K., Hoseinpour, P., Coletti, R., Gold, C., Ishikawa-Ankerhold, H., Lorenz, M., Fingerle-Rowson, G., Bucala, R., Schulz, C. and Massberg, S. (2018). Activation of canonical proinflammatory pathways in smooth muscle cells exerts paradoxical atheroprotective effects. Eur. Heart J., 39. S. 840 - 841. OXFORD: OXFORD UNIV PRESS. ISSN 1522-9645